This share was tipped on Bloomberg as a buy at £4.36. The company makes a profit, with a strong portfolio of drugs that are already sold on the market. It appears to have formed a double bottom with its close on 26th May, 2000 at £4.47. TA signals do not look all that encouraging but it is worth keeping an eye on.
No financial advice intended
Tx
No financial advice intended
Tx